Despite HCC being reported to exhibit a relatively low FAP expression [32] and an intermediate level of mean SUVmax (6–12) compared to other cancer types [33], FAPI PET has demonstrated promising outcomes for HCC primarily because of its minimal liver uptake, resulting in very low background activity. This evidence concerns the gene FAP and hepatocellular carcinoma.